Merck Halts Preladenant Development In Parkinson’s Following Phase III Failures
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Company says it will not pursue regulatory filings for the adenosine-2a receptor antagonist because studies in moderate-to-severe and early-stage disease failed to show sufficient evidence of efficacy.
You may also be interested in...
Merck Comes Prepared This Time As Sugammadex Faces Second Advisory Committee
After failing to submit safety data on time during the drug’s first FDA review, Merck has its data together and is armed with a new hypersensitivity study in advance of the second panel review for its anesthesia product.
Parkinson’s Disease At A Crossroad: Deals And Emerging Therapeutics
The last five years have seen an explosion in novel approaches to Parkinson’s disease.
Shared Strengths: The Merck And Schering Pipelines
Merck’s acquisition of Schering-Plough brings much-needed late-stage assets, including potential blockbusters like TRA and bocepravir; the combined pipelines also strengthens existing footholds in neuroscience and respiratory drugs.